
Larimar Therapeutics, Inc. (Mon, May 13, 2024)

Sell candidate since May 10, 2024 Gain 2.81%



StockInvest.us Gyneju st. 14, "ROCKIT" Vilnius, LT-01109 Lithuania



Frend:	Sell
VV Long:	Buy
VV Short:	Sell
Pivot:	Sell
Volume:	Sell
MACD:	Buy

Tech commentaries:

The Larimar Therapeutics, Inc. stock price gained 2.81% on the last trading day (Monday, 13th May 2024), rising from \$7.12 to \$7.32. During the last trading day the stock fluctuated 7.67% from a day low at \$7.04 to a day high of \$7.58. The price has risen in 6 of the last 10 days and is up by 10.74% over the past 2 weeks. Volume fell on the last day by -156 thousand shares and in total, 206 thousand shares were bought and sold for approximately \$1.50 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies the upper part of a very wide and falling trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break up at the top trend line at **\$7.76** will firstly indicate a slower falling rate, but may be the first sign of a trend shift. Given the current short-term trend, the stock is expected to fall **-43.14%** during the next 3 months and, with a 90% probability hold a price between **\$2.94** and **\$4.41** at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

The Larimar Therapeutics, Inc. stock holds a sell signal from the short-term Moving Average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. On further gains, the stock will meet resistance from the short-term Moving Average at approximately **\$7.77**. On a fall, the stock will find some support from the long-term average at approximately **\$7.19**. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and it may be an early warning. The stock should be watched closely. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Monday, May 06, 2024, and so far it has fallen -11.17%. Further fall is indicated until a new bottom pivot has been found.

Larimar Therapeutics, Inc. finds support from accumulated volume at \$7.22 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. On the upside the stock meets some resistance from accumulated volume at \$8.35, \$8.63 and \$8.77.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved **\$0.540** between high and low, or **7.67%**. For the last week, the stock has had daily average volatility of **6.96%**.

Larimar Therapeutics, Inc. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock. We have upgraded our analysis conclusion for this stock since the last evaluation from a Strong Sell to a Sell candidate.

Risk: High

Disclaimer: StockInvest.us is a research service that provides financial data and technical analysis of stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "StockInvest.us". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy.